Hospira Epogen/Procrit Biosimilar Heads to Panel Meeting

Federal Register notice: FDA has announced a 5/25 Oncologic Drugs Advisory Committee meeting that will discuss a Hospira BLA for a proposed biosimilar product referencing Amgen’s Epogen/Procrit (epoetin alfa), indicated for treating anemia due to certain illnesses. To view the notice, click here.

Read more